Rare Disease

Timber Pharmaceuticals’ CONTROL study evaluated the safety and efficacy of the topical isotretinoin.

At the 2022 National Infusion Center Association Annual Conference, Kelly Gordon, PharmD, answered why diagnosing GPP is so difficult and what to look for to optimize patient care.

Timber Pharmaceuticals has received an FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis.

The 3rd Annual San Diego Dermatology Symposium (SDDS) was held in-person for the first time on March 11 to 13, 2022, at the Hilton San Diego Bayfront, in California.

New research has been published in the New England Journal of Medicine on spesolimab as a treatment for generalized pustular psoriasis.